Purple Biotech
PPBT
19 hedge funds and large institutions have $776K invested in Purple Biotech in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3.18% less ownership
Funds ownership: 9.93% → 6.75% (-3.2%)
56% less capital invested
Capital invested by funds: $1.77M → $776K (-$992K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$38.5K |
| 2 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
+$12.6K |
| 3 |
HF
HRT Financial
New York
|
+$8K |
| 4 |
VVP
Venture Visionary Partners
Sylvania,
Ohio
|
+$3.83K |
| 5 |
VF
Virtu Financial
New York
|
+$1.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$439K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$19.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$19.4K |
| 4 |
Millennium Management
New York
|
-$14.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1.62K |
PPBT Hedge Fund Activity: Q2 2024 in Review
19 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2024, worth a combined $776K — down 56% from $1.77M a quarter earlier.
Fund positioning in PPBT was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $38.5K. The largest seller was Armistice Capital, cutting an estimated $439K.
- 19 institutional investors held Purple Biotech (PPBT) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $776K of Purple Biotech stock for Q2 2024, down 56% quarter-over-quarter.
- 2 funds opened new Purple Biotech positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Purple Biotech buyer in Q2 2024 was Morgan Stanley, an estimated $38.5K added.
- The largest Purple Biotech seller in Q2 2024 was Armistice Capital, an estimated $439K sold.
Based on aggregated 13F filings for Q2 2024.